Stocks in news: Hindustan Copper, HCL Tech, Cadila Healthcare, Adani Ports and more businesstoday.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from businesstoday.in Daily Mail and Mail on Sunday newspapers.
Cadila Healthcare unit inks pact to sell two brands to Integrace outlookindia.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from outlookindia.com Daily Mail and Mail on Sunday newspapers.
India Court Rules on Double Patent in Astrazeneca Case natlawreview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from natlawreview.com Daily Mail and Mail on Sunday newspapers.
India Court Finds Double Patenting in Pharmaceutical Case natlawreview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from natlawreview.com Daily Mail and Mail on Sunday newspapers.
May 17, 2021
Says MRP of medical devices cannot be increased more than 10% in a year
The National Pharmaceutical Pricing Authority of India (NPPA) has fixed the price of two Covid-19 drugs, Budesonide and Dexamethasone, at ₹40.17 per tablet of 9 mg and ₹3.6 per tablet of 6 mg, respectively, exclusive of goods and services tax (GST).
According to an order from the NPPA, while the price cap of Budesonide is for manufacturers Sun Pharmaceutical Industries Ltd and Sun Pharma Laboratories Ltd, the price of Dexamethasone has been fixed for Cadila Healthcare Ltd and Zydus Healthcare Ltd.
MRP of devices
Meanwhile, the NPPA has also ordered that the maximum retail price (MRP) of medical devices such as pulse oximeter and oxygen concentrators cannot be increased by more than 10 per cent in a year. It has asked all manufacturers and importers of pulse oximeter and oxygen concentrators to submit the MRP details in the prescribed format latest by May 22.